Despite underrepresentation of women in cardiac resynchronization therapy studies, it has been conclusively shown that women demonstrate greater benefit than men in functional status, reverse cardiac remodeling, and survival and female gender remains an independent predictor of greater response to cardiac resynchronization therapy after adjustment for various other factors. Eligible female patients are less likely to receive this beneficial therapy and various performance enhancement initiatives can reduce this genderbased disparity with favorable outcomes.
INTRODUCTION
Cardiac Resynchronization Therapy (CRT) is a proven modality for improving survival and reduce hospitalizations in appropriately selected heart failure (HF) patients with low ejection fraction and increased QRS duration [1] [2] [3] [4] [5] .There are significant gender differences in prevalence of disease, physiology, body size, etiology, pathophysiology and clinical course of HF, and many other intrinsic and extrinsic factors. Despite these disparities, present clinical practice guidelines for CRT are not gender-specific and are based on clinical trials where the majority of patients enrolled were men [6, 7] .In this review, we explore gender differences in clinical efficacy of CRT and reasons for this disparity.
Current professional society guidelines reserve the highest (Class I ) recommendation for CRT-defibrillator (CRT-D) implantation in patients with heart failure and reduced ejection fraction, a left bundle branch block (LBBB) and a QRS ≥150ms *8] . For those without LBBB, the recommendations are class IIa or IIb dependent on QRS duration [8] .
Article received on 8 July 2016, published on 30 July 2016. K. Sharada Women are underrepresented in clinical trials of CRTmaking up less than 30% of enrollees. The reasons for lesser proportion of women undergoing CRT could be due to reluctance to undergo CRT implant, concern on the part of physicians for higher procedural complications in women and more prevalence of 'heart failure with preserved ejection fraction' where CRT is not indicated [9] . Despite this fact, analysis of these clinical trials, registry data combined with many other large prospective and retrospective trials shows that women tend to do better with CRT-D than men [9] . (Table 1) The MIRACLE trial enrolled 453 patients with HF with reduced EF (<35 %), NYHA class III or IV and QRS > 130ms and randomized them to CRT or control group. Women constituted 36 % of the total enrolment (144/453). Improvements in both clinical status and cardiac function were seen in the CRT group. Compared with control subjects, women but not men experienced longer times to first HF hospitalization or death with CRT [10] .
GENDER DIFFERENCES IN THE OUTCOME OF LARGE CLINICAL TRIALS
The Multi-centre Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy (MADIT-CRT) enrolled 1,820 patients with NYHA class I and II symptoms, LVEF < 30 % and QRS >130 ms, of whom453 were women 9 .Patients were randomly assigned to CRT-D or ICD alone. Patients in the CRT-D arm experienced a 34 % reduction in the combined endpoint of HF or death. The study pre-specified an analysis by gender and found that the primary outcome of HF or death was seen in11 % of those with CRT-D compared with 20 [12] .
The Resynchronization Reverses Remodeling in Systolic
Left Ventricular Dysfunction (REVERSE) trial evaluated the effects of CRT on the clinical course and LV function in patients with mild HF [12] . There were 684patients enrolled in the trial, with women constituting 20 % of the total enrolment. Patients were randomized to CRT or the control group and a pre-specified analysis of 419 patients with CRT devices turned on was performed. Patients in the CRT-ON group were followed for an additional 5 years, and on multivariable analysis it was found that there was a significant survival benefit for patients with CRT-D devices compared with the control group, with the mortality benefit being larger for women than men.
Xu et al. retrospectively evaluated 728 patients who received CRT with the aim of detecting gender differences in CRT effectiveness. Women constituted 22.8 % (166) of the total sample and had a statistically significant improvement in NYHA class that was not seen in men (p=0.009). A greater improvement in LVEF was also seen in women compared with men [13] . Leyva et al. studied long-term clinical outcomes after CRT implantation in 550 patients, of which 122 (22 %) were women. A Cox proportional hazards analysis showed that women had better survival from death due to any cause as well as cardiovascular death. They also had a lower incidence of the combined end point of cardiovascular death/HF hospitalizations. A greater increase in LVEF and a greater reduction in LV endsystolic volume were seen in women compared with men. These benefits were independent of QRS duration, NYHA class, LVEF, age and other comorbidities [14] . An improvement in echocardiographic parameters in women with CRT was also observed in a study by Lilli et al. They followed 195 patients for 12 months after they received CRT and found that women showed a greater benefit with CRT in the form of decreased LV end diastolic volumes and higher LVEF compared with men. This trial showed that both men and women with ICD/CRT-D derived a significant mortality benefit (men OR, 0. [16] .The lack of CRT benefit in patients without LBBB has also been observed in recent studies [9, 10, 12] .
GENDER DIFFERENCES IN LBBB OCCURRENCE AND NEW GENDER-SPECIFIC CRITERIA
Women with heart failure have a higher percentage of LBBB than men (85% vs 69%) [6] . However, the difference is likely even greater because men have longer QRS durations than women [17] and are more likely to have a false-positive LBBB diagnosis [18] . New gender-specific strict LBBB criteria were proposed that require a QRS of 130 milliseconds or longer in women and 140 milliseconds or longer in men, along with mid-QRS notching and/or slurring [18] . Recent single-center studies demonstrated that patients not meeting strict LBBB criteria had a 4-fold higher rate of heart failure hospitalization or death and did not respond to CRT-D compared with patients who met the strict LBBB criteria [19, 20] . Patients without LBBB receiving CRT-D had a lower mortality risk than non-LBBBICD patients, although the difference was small (absolute risk difference of 2% in men and 3% in women) [21] . A small beneficial effect of CRT has also been observed for certain patients without LBBB in previous studies and may be caused by multiple factors [22] . A recent post hoc analysis of MADIT-CRT found that patients with non-LBBB who had extremely long PR intervals at baseline benefited from CRT. This suggests that optimizing atrioventricular delay may provide some benefit in these patients [22] .
GENDER DIFFERENCES IN RESPONSE TO CRT WITH VARYING QRS DURATION IN LBBB
Zusterzeel et al. [6] , with no similar benefit in men with similar findings. The relationship between gender and response to CRT with varying QRS durations in patients with LBBB was further studied by Varma et al. [23] .Patients with NYHA class III/IV HF, non-ischaemic cardiomyopathy and LBBB with a CRT device were followed for a period of 2 years. A total of 212 patients were enrolled of which 49.5 % (104) were women. The overall positive response rate in both genders was 76 % in those with a QRS >150 ms, and 58 % in those with a QRS <150 ms. However, women had a higher response rate than men at a QRS <150 ms (86 %in women versus 36 % in men; p<0.001). These studies indicate that the relationship between QRS duration and response to CRT is different between men and women.
One reason why women might benefit more from CRT than men at shorter QRS durations may be that women normally have shorter QRS durations than men [17] . Thus, any particular degree of QRS prolongation is relatively longer in women compared with men and may indicate greater dys-synchrony. By not considering gender-related differences in response to CRT, there is a possibility that physicians might exclude female patients with shorter QRS durations who would benefit from CRT.
REASONS FOR BETTER CRT RESPONSE IN WOMEN WITH HEART FAILURE
It is thus evident that female gender as a positive predictor of response to CRT. This is attributable to women having higher prevalence of non ischemic cardiomyopathy (55% vs 30%) and higher rate of 'left bundle branch block' (LBBB) configuration (81% vs 61%) -both factors shown to correlate with good CRT response [6, 24] . Also women with HF have lower rates of atrial fibrillation/flutter (23% vs 34%) and ischemic HF causes which have been associated with CRT non responder state [22] . While controlling for these variables does not affect the results, it is difficult to differentiate the effect of LBBB vs non ischemic cardiomyopathy because, as demonstrated by a recent cardiac magnetic resonance study [25] , complete LBBB in patients referred for ICD and CRT-D is most commonly caused by non ischemic cardiomyopathies.
GENDER DIFFERENCES IN CRT UTILIZATION
Despite the overall prevalence of HF in women being slightly less than that of men, a study sponsored by the Agency for Healthcare Research and Quality revealed that hospital admissions for HF exacerbations or HFrelated complications have been higher among female HF patients than male patients. This trend has been consistent over the past three decades [26] . .This disparity remained even after adjusting for the lower incidence of CHF in women. Thus despite a clear mortality benefit seen with CRT in women, this life saving therapy is still significantly underutilized in women [7] .
The IMPROVE HF [27] study evaluated whether a program to provide clinical decision-making support tools and educational materials to healthcare providers would lead to similar improvements in adherence to clinical practice guidelines for both male and female patients. This was a prospective study where high-risk patients with HF with reduced EF (<35 %) eligible for treatment with an ICD, CRT or several other guidelinerecommended therapies were identified and hospitals were provided with clinical algorithms, pocket cards, patient educational materials and patient assessment forms and were followed for 24 months. The study included a total of 15,170patients of whom 4,383 (28.9 %) were women. At the end of 2 years, rates of ICD use went up from 40-50 % to 75-80 % and CRT use from35-40 % to 65-75 % in both men and women. Thus, providing clinical decision-making support and education can lead to better CRT therapy utilization in eligible patients irrespective of gender.
CONCLUSION
Women are underrepresented in clinical trials of cardiac resynchronization therapy but have better prognosis than men after the device therapy and special efforts should be directed at reaching women for this lifesaving therapy. 
